SEC Filings

10-Q
MEDTRONIC PLC filed this Form 10-Q on 09/01/2017
Entire Document
 


flows. We assess the impairment of goodwill at the reporting unit level annually in the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Goodwill was $39.2 billion and $38.5 billion at July 28, 2017 and April 28, 2017, respectively.
We test definite-lived intangible assets for impairment when an event occurs or circumstances change that would indicate the carrying amount of the assets or asset group may be impaired. Our tests are based on future cash flows that require significant judgment with respect to future revenue and expense growth rates, appropriate discount rates, asset groupings, and other assumptions and estimates. We use estimates that are consistent with our business plans and a market participant view of the assets being evaluated. Actual results may differ from our estimates due to a number of factors including, among others, changes in competitive conditions, timing of regulatory approval, results of clinical trials, changes in worldwide economic conditions, and fluctuations in currency exchange rates. Definite-lived intangible assets, net of accumulated amortization, were $22.4 billion and $22.8 billion at July 28, 2017 and April 28, 2017, respectively.
We assess the impairment of indefinite-lived intangibles annually in the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Our impairment tests of indefinite-lived intangibles require us to make several estimates about fair value, including projected future cash flows and the appropriate discount rates. Indefinite-lived intangible assets were $569 million and $594 million at July 28, 2017 and April 28, 2017, respectively.
Contingent Consideration Contingent consideration liabilities are recorded at the acquisition date at estimated fair value and are remeasured each reporting period with the change in fair value recognized within acquisition-related items in our consolidated statements of income. Changes to the fair value of contingent consideration may result from changes in the estimated timing and amount of revenue, estimated timing or probability of achieving the milestones which trigger payment, or discount rates. The fair value of contingent consideration liabilities was $242 million and $246 million at July 28, 2017 and April 28, 2017, respectively.
NEW ACCOUNTING PRONOUNCEMENTS
Information regarding new accounting pronouncements is included in Note 2 to the current period's consolidated financial statements.
ACQUISITIONS
Information regarding acquisitions is included in Note 3 to the current period's consolidated financial statements.
NET SALES
The table below illustrates net sales by operating segment and division for the three months ended July 28, 2017 and July 29, 2016:
 
Three months ended
 
 
(in millions)
July 28, 2017
 
July 29, 2016
 
% Change
Cardiac Rhythm & Heart Failure
$
1,390

 
$
1,334

 
4
 %
Coronary & Structural Heart
817

 
762

 
7

Aortic & Peripheral Vascular
439

 
422

 
4

Cardiac and Vascular Group
2,646

 
2,518

 
5

Surgical Solutions
1,399

 
1,348

 
4

Patient Monitoring & Recovery
1,087

 
1,076

 
1

Minimally Invasive Therapies Group
2,486

 
2,424

 
3

Spine
649

 
645

 
1

Brain Therapies
522

 
489

 
7

Specialty Therapies
369

 
356

 
4

Pain Therapies
269

 
282

 
(5
)
Restorative Therapies Group
1,809

 
1,772

 
2

Diabetes Group
449

 
452

 
(1
)
Total
$
7,390

 
$
7,166

 
3
 %

50

X